A 4-Week, Open-Label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With up-Titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity.

Trial Profile

A 4-Week, Open-Label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With up-Titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2013

At a glance

  • Drugs Darifenacin (Primary)
  • Indications Detrusor instability
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2006-002361-39).
    • 23 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top